Drug company Merck & Co. is recalling its entire U.S. stock of the new combination cholesterol pill Liptruzet because of a packaging defect. The recall affects every batch from all four strength doses of the pill.
Liptruzet was approved by the Food and Drug Administration (FDA) in May. It is a combination of the ezetimibe (the active ingredient in Zetia) and atorvastatin (the drug ingredient in the statin Lipitor). Liptruzet is designed to help block the absorption of cholesterol that comes from food, as well as reduce the cholesterol the body makes naturally based on family history. It can also help lower total cholesterol and triglycerides, as well as raise levels of HDL, or “good” cholesterol. Both ezetimibe and atorvastatin are still available as individual treatments.
The recall was initiated because some of the foil pouches holding the pills were found to be defective, which could allow air or moisture inside. Because of this, there is a remote chance that the drug’s effectiveness could be decreased or its properties changed. To date, there are no reports of patient harm or injury.
Patients can continue to use any Liptruzet they have on hand and should talk with their doctors before they stop taking the medication. Merck says it plans to have the drug back on the market as soon as possible.
Any side effects from Liptruzet should be reported to the FDA MedWatch Adverse Event Reporting Program at www.FDA.gov/MedWatch/Report.htm.
Source: Fox News